Patents by Inventor Charles L. Sawyers

Charles L. Sawyers has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MODULATORS OF RESISTANT ANDROGEN RECEPTOR
    Publication number: 20170320849
    Abstract: The present invention provides compounds useful as modulators, agonists or antagonists of androgen receptor (AR), compositions thereof, and methods of making and using the same.
    Type: Application
    Filed: May 12, 2017
    Publication date: November 9, 2017
    Inventors: Minna D. Balbas, Michael J. Evans, Charles L. Sawyers, Yang Shen, David Hosfield, Geoffrey L. Greene
  • Modulators of resistant androgen receptor
    Patent number: 9650359
    Abstract: The present invention provides compounds useful as modulators, agonists or antagonists of androgen receptor (AR), compositions thereof, and methods of making and using the same.
    Type: Grant
    Filed: May 18, 2016
    Date of Patent: May 16, 2017
    Assignee: Memorial Sloan-Kettering Cancer Center
    Inventors: Minna D. Balbas, Michael J. Evans, Charles L. Sawyers, Yang Shen, David Hosfield, Geoffrey L. Greene
  • ANDROGEN RECEPTOR MODULATOR FOR THE TREATMENT OF PROSTATE CANCER AND ANDROGEN RECEPTOR-ASSOCIATED DISEASES
    Publication number: 20170014399
    Abstract: Described herein, inter alia, are compounds useful for the prevention or treatment of hyperproliferative diseases or disorders.
    Type: Application
    Filed: June 13, 2016
    Publication date: January 19, 2017
    Inventors: Michael E. Jung, Charles L. Sawyers, Samedy Ouk, Chris Tran, John Wongvipat
  • SGK1 INHIBITORS FOR TREATMENT OF PROSTATE CANCER
    Publication number: 20170014391
    Abstract: The present invention encompasses the recognition that reproducible and detectable changes in the level and or activity of SGK1 are associated with incidence and/or risk of Castration Resistant Prostate Cancer (CRPC) and/or doubly resistant prostate cancer, specifically in individuals having prostate cancer and on antiandrogen therapy, and provides for the use of SGK1 inhibitors to treat and/or reduce risk of CRPC and/or doubly resistant prostate cancer. In some embodiments, SGK1 inhibitors also have Glucocorticoid Receptor (GR) and/or Androgen Receptor (AR) inhibitory activity or are administered in conjunction with GR and/or AR inhibitors.
    Type: Application
    Filed: December 11, 2014
    Publication date: January 19, 2017
    Inventors: Vivek Arora, Charles L. Sawyers
  • GLUCOCORTICOID INHIBITORS FOR TREATMENT OF PROSTATE CANCER
    Publication number: 20160289261
    Abstract: The present invention encompasses the recognition that reproducible and detectable changes in the level and or activity of Glucocorticoid Receptor (GR) are associated with incidence and/or risk of Castration Resistant Prostate Cancer (CRPC) and/or doubly resistant prostate cancer, specifically in individuals having prostate cancer and on antiandrogen therapy, and provides for the use of GR inhibitors to treat and/or reduce risk of CRPC and/or doubly resistant prostate cancer. In some embodiments, GR inhibitors also have Androgen Receptor (AR) inhibitory activity or are administered in conjunction with AR inhibitors. The present invention also provides technologies for identification and/or characterization of agents to treat and/or reduce risk of CRPC and/or doubly resistant prostate cancer; in some embodiments such agents alter level and/or activity of a GR. In some embodiments, provided agents show effects on a GR's activity of regulating transcription of one or more target genes.
    Type: Application
    Filed: December 11, 2014
    Publication date: October 6, 2016
    Inventors: Vivek Arora, Charles L. Sawyers, Michael J. Evans, Darren R. Veach
  • MODULATORS OF RESISTANT ANDROGEN RECEPTOR
    Publication number: 20160257666
    Abstract: The present invention provides compounds useful as modulators, agonists or antagonists of androgen receptor (AR), compositions thereof, and methods of making and using the same.
    Type: Application
    Filed: May 18, 2016
    Publication date: September 8, 2016
    Inventors: Minna D. Balbas, Michael J. Evans, Charles L. Sawyers, Yang Shen, David Hosfield, Geoffrey L. Greene
  • Substituted diazaspiroalkanes as androgen receptor modulators
    Patent number: 9388159
    Abstract: This invention provides for compounds of the Formula II: wherein A, B, Het, R1, R2 and R3 are as described herein. These compounds are androgen receptor modulators useful for the treatment of androgen receptor-associated conditions.
    Type: Grant
    Filed: June 27, 2014
    Date of Patent: July 12, 2016
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Michael E. Jung, Charles L. Sawyers, Samedy Ouk, Chris Tran, John Wongvipat
  • Modulators of resistant androgen receptor
    Patent number: 9365542
    Abstract: The present invention provides compounds useful as modulators, agonists or antagonists of androgen receptor (AR), compositions thereof, and methods of making and using the same. Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful in medicine, and particularly for treating any of a variety of diseases, disorders or conditions.
    Type: Grant
    Filed: October 25, 2013
    Date of Patent: June 14, 2016
    Assignee: Memorial Sloan-Kettering Cancer Center
    Inventors: Minna D. Balbas, Michael J. Evans, Charles L. Sawyers, Yang Shen, David Hosfield, Geoffrey L. Greene
  • MUTATIONS IN THE BCR-ABL TYROSINE KINASE ASSOCIATED WITH RESISTANCE TO STI-571
    Publication number: 20160130655
    Abstract: The invention described herein relates to novel genes and their encoded proteins, termed Mutants Associated with Resistance to STI-571 (e.g., T315I Bu-Abl), and to diagnostic and therapeutic methods and compositions useful in the management of various cancers that express MARS. The invention further provides methods for identifying molecules that bind to and/or modulate the functional activity of MARS.
    Type: Application
    Filed: June 12, 2015
    Publication date: May 12, 2016
    Inventors: Charles L. Sawyers, Mercedes E. Gorre, Neil Pravin Shah, John Nicoll
  • Biomarker for sensitivity to mTOR inhibitor therapy in kidney cancer
    Patent number: 9261498
    Abstract: The invention disclosed herein provides methods for the examination and/or quantification of biochemical pathways that are disregukted in pathologies such as cancer and to reagents and kits adapted for performing such methods. For example a correlation between VHL loss and mTOR inhibitor sensitivity in human kidney cancer cells is disclosed, indicating that VHL loss confers autonomous and angiogenic competitive advantages to such cells.
    Type: Grant
    Filed: March 17, 2006
    Date of Patent: February 16, 2016
    Assignee: The Regents of the University of California
    Inventors: Charles L. Sawyers, George V. Thomas
  • MODULATORS OF RESISTANT ANDROGEN RECEPTOR
    Publication number: 20150274693
    Abstract: The present invention provides compounds useful as modulators, agonists or antagonists of androgen receptor (AR), compositions thereof, and methods of making and using the same. Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful in medicine, and particularly for treating any of a variety of diseases, disorders or conditions.
    Type: Application
    Filed: October 25, 2013
    Publication date: October 1, 2015
    Inventors: Minna D. Balbas, Michael J. Evans, Charles L. Sawyers, Yang Shen, David Hosfield, Geoffrey L. Greene
  • ANDROGEN RECEPTOR VARIANTS AND METHODS FOR MAKING AND USING
    Publication number: 20150265587
    Abstract: The present invention encompasses the recognition that an F876L mutation of the androgen receptor (AR) gene confers resistance to the antiandrogens enzalutamide (MDV3100) and ARN-509 and is associated with incidence and/or risk of castration resistant prostate cancer (CRPC). The present invention also provides other AR polypeptide sequences associated with increased incidence and/or risk of CRPC. The present invention also provides screening methods for identification and/or characterization of novel AR polypeptide sequences associated with increased incidence and/or risk of CRPC via exposure to antiandrogens and for identification and/or characterization of agents to treat and/or reduce risk of CRPC by virtue of their effect on AR transcriptional activation.
    Type: Application
    Filed: October 25, 2013
    Publication date: September 24, 2015
    Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Minna D. Balbas, Charles L. Sawyers, Philip Watson
  • Treatment of hyperproliferative disorders with diarylhydantoin compounds
    Patent number: 9126941
    Abstract: The present invention relates to diarylhydantoin compounds, including diarylthiohydantoins, and methods for synthesizing them and using them in the treatment of hormone refractory prostate cancer.
    Type: Grant
    Filed: April 17, 2012
    Date of Patent: September 8, 2015
    Assignee: The Regents of the University of California
    Inventors: Charles L. Sawyers, Michael E. Jung, Charlie D. Chen, Samedy Ouk, Chris Tran, John Wongvipat
  • Mutations in the Bcr-Abl tyrosine kinase associated with resistance to STI-571
    Patent number: 9085644
    Abstract: The invention described herein relates to novel genes and their encoded proteins, termed Mutants Associated with Resistance to STI-571 (e.g., T315I Bcr-Abl), and to diagnostic and therapeutic methods and compositions useful in the management of various cancers that express MARS. The invention further provides methods for identifying molecules that bind to and/or modulate the functional activity of MARS.
    Type: Grant
    Filed: July 12, 2012
    Date of Patent: July 21, 2015
    Assignee: The Regents of the University of California
    Inventors: Charles L. Sawyers, Mercedes E. Gorre, Neil Pravin Shah, John Nicoll
  • Mutations in the BCR-ABL tyrosine kinase associated with resistance to STI-571
    Patent number: 9056924
    Abstract: The invention described herein relates to novel genes and their encoded proteins, termed Mutants Associated with Resistance to STI-571 (e.g., T315I Bcr-Abl), and to diagnostic and therapeutic methods and compositions useful in the management of various cancers that express MARS. The invention further provides methods for identifying molecules that bind to and/or modulate the functional activity of MARS.
    Type: Grant
    Filed: April 4, 2008
    Date of Patent: June 16, 2015
    Assignee: The Regents of the University of California
    Inventors: Charles L. Sawyers, Mercedes E. Gorre, Neil Pravin Shah, John Nicoll
  • DIARYLHYDANTOIN COMPOUNDS
    Publication number: 20150112082
    Abstract: The present invention relates to diarylhydantoin compounds, including diarylthiohydantoins, and methods for synthesizing them and using them in the treatment of hormone refractory prostate cancer.
    Type: Application
    Filed: September 25, 2014
    Publication date: April 23, 2015
    Inventors: Charles L. Sawyers, Michael Jung, Charlie D. Chen, Samedy Ouk, Derek Welsbie, Chirs Tran, John Wongvipat, Dongwon Yoo
  • DIARYLHYDANTOIN COMPOUNDS
    Publication number: 20150065546
    Abstract: The present invention relates to diarylhydantoin compounds and methods for synthesizing them and using them in the treatment of hormone refractory prostate cancer.
    Type: Application
    Filed: March 24, 2014
    Publication date: March 5, 2015
    Applicant: The Regents of the University of California
    Inventors: Michael E. Jung, Dongwon Yoo, Charles L. Sawyers, Chris Tran, John Wongvipat
  • DIARYLTHIOHYDANTOIN COMPOUNDS
    Publication number: 20140343111
    Abstract: The present invention relates to diarylthiohydantoin compounds and methods for synthesizing them and using them in the treatment of hormone refractory prostate cancer.
    Type: Application
    Filed: December 20, 2013
    Publication date: November 20, 2014
    Applicant: The Regents of the University of California
    Inventors: Charles L. Sawyers, Michael E. Jung, Charlie D. Chen, Samedy Ouk, Chris Tran, John Wongvipat, Dongwon Yoo
  • ANDROGEN RECEPTOR MODULATOR FOR THE TREATMENT OF PROSTATE CANCER AND ANDROGEN RECEPTOR-ASSOCIATED DISEASES
    Publication number: 20140309262
    Abstract: Described herein, inter alia, are compounds useful for the prevention or treatment of hyperproliferative diseases or disorders.
    Type: Application
    Filed: June 27, 2014
    Publication date: October 16, 2014
    Inventors: Michael E. Jung, Charles L. Sawyers, Samedy Ouk, Chris Tran, John Wongvipat
  • Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
    Patent number: 8802689
    Abstract: Described herein, inter alia, are compounds useful for the prevention or treatment of hyperproliferative diseases or disorders.
    Type: Grant
    Filed: September 13, 2012
    Date of Patent: August 12, 2014
    Assignee: The Regents of the University of California
    Inventors: Michael E. Jung, Charles L. Sawyers, Samedy Ouk, Chris Tran, John Wongvipat